Heart disease and stroke statistics—2022 update: a report from the American Heart Association

CW Tsao, AW Aday, ZI Almarzooq, A Alonso… - Circulation, 2022 - Am Heart Assoc
Background: The American Heart Association, in conjunction with the National Institutes of
Health, annually reports the most up-to-date statistics related to heart disease, stroke, and …

Heart disease and stroke statistics—2023 update: a report from the American Heart Association

CW Tsao, AW Aday, ZI Almarzooq, CAM Anderson… - Circulation, 2023 - Am Heart Assoc
Background: The American Heart Association, in conjunction with the National Institutes of
Health, annually reports the most up-to-date statistics related to heart disease, stroke, and …

[HTML][HTML] Current and novel biomarkers of thrombotic risk in COVID-19: a consensus statement from the international COVID-19 thrombosis biomarkers colloquium

DA Gorog, RF Storey, PA Gurbel, US Tantry… - Nature Reviews …, 2022 - nature.com
Abstract Coronavirus disease 2019 (COVID-19) predisposes patients to thrombotic and
thromboembolic events, owing to excessive inflammation, endothelial cell activation and …

Efficacy and safety of therapeutic-dose heparin vs standard prophylactic or intermediate-dose heparins for thromboprophylaxis in high-risk hospitalized patients with …

AC Spyropoulos, M Goldin, D Giannis… - JAMA internal …, 2021 - jamanetwork.com
Importance Hospitalized patients with COVID-19 are at risk for venous and arterial
thromboembolism and death. Optimal thromboprophylaxis dosing in high-risk patients is …

[HTML][HTML] Therapeutic anticoagulation with heparin in noncritically ill patients with Covid-19

ATTACC, ACTIV-4a, and REMAP-CAP … - New England Journal …, 2021 - Mass Medical Soc
Background Thrombosis and inflammation may contribute to the risk of death and
complications among patients with coronavirus disease 2019 (Covid-19). We hypothesized …

Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid …

M Sholzberg, GH Tang, H Rahhal, M AlHamzah… - bmj, 2021 - bmj.com
Objective To evaluate the effects of therapeutic heparin compared with prophylactic heparin
among moderately ill patients with covid-19 admitted to hospital wards. Design Randomised …

Effect of antithrombotic therapy on clinical outcomes in outpatients with clinically stable symptomatic COVID-19: the ACTIV-4B randomized clinical trial

JM Connors, MM Brooks, FC Sciurba, JA Krishnan… - Jama, 2021 - jamanetwork.com
Importance Acutely ill inpatients with COVID-19 typically receive antithrombotic therapy,
although the risks and benefits of this intervention among outpatients with COVID-19 have …

[HTML][HTML] ISTH guidelines for antithrombotic treatment in COVID‐19

S Schulman, M Sholzberg, AC Spyropoulos… - Journal of Thrombosis …, 2022 - Elsevier
Antithrombotic agents reduce risk of thromboembolism in severely ill patients. Patients with
coronavirus disease 2019 (COVID‐19) may realize additional benefits from heparins …

American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19

A Cuker, EK Tseng, R Nieuwlaat… - Blood …, 2021 - ashpublications.org
Background: Coronavirus disease 2019 (COVID-19)–related critical illness and acute illness
are associated with a risk of venous thromboembolism (VTE). Objective: These evidence …

[HTML][HTML] Outpatient pulmonary rehabilitation in patients with long COVID improves exercise capacity, functional status, dyspnea, fatigue, and quality of life

S Nopp, F Moik, FA Klok, D Gattinger, M Petrovic… - Respiration, 2022 - karger.com
Background: COVID-19 survivors face the risk of long-term sequelae including fatigue,
breathlessness, and functional limitations. Pulmonary rehabilitation has been …